Publier
Happy_shanky
🚨 $LLY — ELI LILLY’S NEXT OBESITY DRUG SHOWS STRONG RESULTS
ELI LILLY’S EXPERIMENTAL ELORALINTIDE, WHEN COMBINED WITH ZEPBOUND, PRODUCED AN AVERAGE 23.3% WEIGHT LOSS OVER AROUND 11 MONTHS.
THAT COMPARES WITH 14.8% FOR ZEPBOUND ALONE IN PATIENTS WITH TYPE 2 DIABETES.
⚠️ HOWEVER, 11%–27% OF PATIENTS STOPPED THE COMBINATION DUE TO SIDE EFFECTS, KEEPING TOLERABILITY AS AN IMPORTANT CONSIDERATION.
LILLY EXPECTS TO MOVE ELORALINTIDE INTO LATE-STAGE TRIALS LATER THIS YEAR.
#DailyOrbit
Avertissement : les contenus d'OKX Orbit sont uniquement publiés à titre informatif. En savoir plus
Réponses
Aucun commentaire pour le moment. Soyez le premier à répondre !
Cryptos tendance
BTC/USDTBitcoin
$86 412,2+0,03 %
ETH/USDTEthereum
$2 745,1+0,02 %
SOL/USDTSolana
$121,76+0,04 %
Tendances du marché
1#USJobsDataToday
2#BTCETHETFOutflows
3#USTreasuryYieldsSurge
